Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Most COVID-19 vaccines are injected into the arm or leg ... Diamond and Curiel inserted a gene from SARS-CoV-2, the virus that causes COVID-19, into a harmless virus known as an adenovirus. The ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, ...

The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.